Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
Lan-Ping Xu,Pei-Hua Lu,De-Pei Wu,He Huang,Er-Lie Jiang,Dai-Hong Liu,Wei-Jie Cao,Xi Zhang,Yue-Wen Fu,Nai-Nong Li,Xin-Chuan Chen,Xiao-Yu Zhu,Qi-Fa Liu,Ling-Hui Xia,Yi-Cheng Zhang,Ya-Jing Xu,Fu-Chun Li,Jiong Hu,Si-Xi Liu,Rong-Rong Liu,Xiao-Di Ma,Xiao-Wen Tang,Yi Luo,Xiao-Hui Zhang,Xiao-Jun Huang
DOI: https://doi.org/10.1038/s41409-024-02419-8
2024-09-26
Bone Marrow Transplantation
Abstract:Over past two years, a total of 39,918 hematopoietic stem cell transplantation (HSCT) cases were reported, with 18,194 and 21,714 transplants performed in 2022 and 2023, respectively. Autologous HSCT accounted for 6562 cases (31%) in 2022, while allogeneic HSCT comprised 12,632 cases (69%). In 2023, the number of allogeneic HSCTs exceeded 15,000, maintaining a 69% share. Participation in the 2022 and 2023 surveys included 193 and 212 transplantation teams, respectively, from 27 provinces, municipalities, or autonomous regions. The leading indication of HSCT was acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and mixed phenotype acute leukemia, with a total of 17,421 cases. AML was the most common disease (10,339, 38%) for allogeneic HSCT, which was followed by ALL (5925 cases, 21%). Peripheral blood emerged as the primary source of stem cell grafts, utilized in 54% of matched sibling donor transplants and 77% of haploidentical donor transplants. The BuCy-based conditioning regimen was the most prevalent, used in 53% of allogeneic HSCT cases in the past two years. This survey offers a comprehensive overview of the current HSCT landscape and serves as a valuable resource for clinical practice.
oncology,immunology,hematology,transplantation